Osteosarcoma (OS) is a malignant tumor of mesenchymal origin that produces osteoid.
Introduction

56
Osteosarcoma (OS) is a malignant tumor of mesenchymal origin that produces osteoid.
57
In dogs, OS most frequently occurs in large and giant breeds (Cooley and 
Materials and Methods
88
The effects of the different chemotherapeutics compared to no chemotherapy were 89 determined using individual patient data (IPD). These IPD were used previously in an IPD in these studies were diagnosed with osteosarcoma. For the present analysis, dogs were 99 excluded if they did not receive surgery; due to euthanasia (n = 197), who received limb-100 sparing surgery (n = 41), who received an infrequently used chemotherapeutic protocol (n = 101 13) or who received radiation therapy (n =11). Additionally, the study by Sottnik ( In the following section, the performance of this prediction model is described. that the predicted risk was too small for dogs with a low observed risk and too large for dogs 148 with a higher observed risk, however these discrepancies were small (Appendix Figure A) .
149
All performance measures were corrected for optimism using 100 bootstrap samples Data analysis: predicting 5-month mortality 166 An individual dogs' risk of 5-month mortality, under no chemotherapy, was predicted 167 using the coefficient presented in Table 1 and by setting the chemotherapy to zero (no For the subset of 400 dogs on average 12.6% of the information was missing; 246 specifically, 5-month mortality 9%, chemotherapy 7.5%, tumor location 9.5%, gender 5.3%, 247 neuter status 5.3%, age 6.5%, weight 26.3%, high SALP 57,5% and breed 4.5%, (see Table 2 248 for an overview). Again missing values were imputed as previously described. 
Results
282
Baseline characteristics of the 406 included dogs are presented in Table 2 comparisons were similar; with the possible exception of the cisplatin effect, which was non-295 significant (Table 3) . (Figures 2 and 3) .
307
The results of the sensitivity analysis of excluding those subjects who died within the 308 first month are depicted in Table 4 . The main effect estimates were closer to the null than in best of our knowledge, our study is the first to explore whether chemotherapy effects vary 326 according to baseline mortality risk (using multiple variables).
328
The current study has some limitations. First, only data from nonrandomized studies 
